Preparation method and application of neutrophil cascade targeting drug delivery system
Through a drug delivery system targeted by neutrophil cascade, the NEBP peptide and MMP9-responsive peptide-coupled polypeptide NEMSS is modified with DSPE-PEG2K-Maleimide, and combined with CsA to form CsA-M-Neu-NPs nanodrugs, which solves the problem. The challenge of drug delivery in cerebral ischemia and reperfusion injury has achieved effective targeted delivery and therapeutic effects.
Patent Information
- Application Number
- CN202410729125.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-06
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-06-06
AI Technical Summary
Drug delivery for cerebral ischemia-reperfusion injury faces challenges such as blood-brain barrier and lesion site identification, and it is difficult for the prior art to effectively target drug delivery to the ischemia-injured site.
Using a drug delivery system targeted by neutrophil cascade, the polypeptide NEMSS with MMP9 response and targeting neutrophils and mitochondria is formed and targeted with DSPE -PEG2K-Maleimide surface modification, combining circuminin A (CsA) and Cy5 dye, forms CsA-M-Neu-NPs nanodrugs, and uses ultrasound technology to prepare spherical nanodrugs.
Successfully targeted neutrophils and mitochondria, penetrated the blood-brain barrier, significantly alleviated brain tissue infarction and neurological damage, and provided a new idea for the treatment of cerebral ischemia and reperfusion injury.
Smart Images

Figure CN118948796A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a preparation method and application of a neutrophil cascade-targeted drug delivery system. Background Art
[0002] Cyclosporin A (CsA) is an immunosuppressant that can bind to the cyclophilin family. It inhibits the opening of the mitochondrial permeability transition pore (mPTP) by binding to the CypD protein in mitochondria. Studies have shown that the opening and overexpression of mPTP are important upstream signaling pathways of the mitochondrial dysfunction cascade during ischemic injury, which can cause a decrease in adenosine triphosphate (ATP) production and an excessive increase in ROS, ultimately leading to cell dysfunction and even death. Therefore, mPTP is considered a potential target for drugs in ischemic diseases. CsA has a clear inhibitory effect on the opening of mPTP, which can reduce mitochondrial damage, change mitochondrial ATP energy metabolism, and maintain mitochondrial homeostasis. It may be an effective strategy to reduce organ ischemia-reperfusion injury.
[0003] Drug treatment of cerebral ischemia-reperfusion injury (CIRI) faces multiple continuous obstacles (blood-brain barrier (BBB), lesion site identification, etc.), making drug delivery challenging. Studies on the brain microenvironment of CIRI have shown that secondary inflammatory responses occur after CIRI, including the recruitment of leukocytes to the stroke core and penumbra. Neutrophils (PMNs) are the most abundant leukocytes in humans (50% to 70%), and they function in the innate immune response to infection or tissue damage through phagocytosis, degranulation, etc. Therefore, PMNs can be used to load drug molecules, and with their own inflammatory properties and cross-BBB effects, they can autonomously guide the targeted delivery of drugs for CIRI processes with inflammatory responses. In addition, during the CIRI process, the content of metalloproteinase MMP-9 in the ischemic injury site increases significantly, which is a potential trigger for drug release.
[0004] Based on this, we propose a preparation method and application of a neutrophil cascade-targeted drug delivery system. Summary of the invention
[0005] In view of the deficiencies of the prior art, the present invention proposes a preparation method and application of a neutrophil cascade-targeted drug delivery system.
[0006] The purpose of the present invention can be achieved through the following technical solutions:
[0007] A method for preparing a neutrophil cascade-targeted drug delivery system, the preparation method comprising the following steps:
[0008] S1. The NEBP peptide targeting neutrophils (sequence: CGEAIPMSIPPEVK), the MMP9 response peptide (sequence: PVGLIG) and the mitochondria-targeted peptide SS-31 (sequence: H2N-DArg-Dmt-Lys-Phe-NH2) were coupled to obtain the peptide NEMSS (sequence: DArg-Dmt-Lys(Cys)-Phe-PVGLIG-GEAIPMSI PPEVK) that is MMP9-responsive and simultaneously targets neutrophils and mitochondria;
[0009] S2, using DSPE-PEG2K-Maleimide as a raw material, modifying the surface of DSPE-PEG2K-Maleimide with a peptide NEMSS that responds to MMP9 and targets neutrophils and mitochondria to form a polymer;
[0010] S3. The polymer, cyclosporin A (CsA), Cy5 dye, cholesterol and lipid are mixed in an organic solvent, vacuum dried into a thin film, and then phosphate buffered saline (PBS) is added and ultrasonicated for 10 minutes to obtain a neutrophil cascade-targeted drug delivery system.
[0011] Preferably, the molar ratio of the NEBP peptide, the MMP9 responsive peptide and the mitochondrial targeted polypeptide SS-31 is 1:1:1.
[0012] Preferably, the molar ratio of DSPE-PEG2K-Maleimide to NEMSS polypeptide is 1:1.
[0013] Preferably, the molar ratio of the polymer, CsA drug, and Cy5 dye is 5:1:0.2
[0014] Preferably, the organic solvent is dichloromethane.
[0015] A neutrophil cascade-targeted drug delivery system is prepared by the above-mentioned method for preparing a neutrophil cascade-targeted drug delivery system.
[0016] Preferably, the CsA-M-Neu-NPs nanodrug presents a spherical structure, and the particle size of the CsA-M-Neu-NPs nanodrug is 90 to 200 nm.
[0017] The use of the above-mentioned neutrophil cascade-targeted drug delivery system in the preparation of drugs for treating cerebral ischemia-reperfusion injury.
[0018] Application of the above-mentioned neutrophil cascade-targeted drug delivery system in the preparation of a drug carrier targeting neutrophils.
[0019] Beneficial effects of the present invention:
[0020] 1. The present invention successfully constructed a neutrophil and mitochondrial targeting polypeptide NEMSS with MMP-9 response through animal experiments, immunofluorescence, magnetic resonance imaging, transmission electron microscopy, and cell experimental techniques, and loaded the mPTP inhibitor CsA to self-assemble into CsA-M-Neu-NPs nanomedicine. Its ability to target neutrophils and mitochondria was verified through cell experiments, providing new ideas for the treatment of tumors, inflammation, immune and other diseases related to neutrophils; at the same time, it was verified that CsA-M-Neu-NPs nanomedicine has a positive effect on the treatment of cerebral ischemia-reperfusion injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0022] Figure 1 The present invention is a flow chart of the preparation of the neutrophil cascade-targeted drug delivery system;
[0023] Figure 2 This is a transmission electron microscopic image of the neutrophil cascade-targeted drug delivery system of the present invention;
[0024] Figure 3 The results of the neutrophil cascade-targeted drug delivery system of the present invention targeting mitochondria in neutrophils and PC12 cells are shown in Figure 1: (A) the neutrophil cascade-targeted drug delivery system targeting neutrophils; (B) the neutrophil cascade-targeted drug delivery system targeting mitochondria;
[0025] Figure 4 The ability of the neutrophil cascade-targeted drug delivery system of the present invention to penetrate the blood-brain barrier and target the site of injury;
[0026] Figure 5 The drug delivery system targeting the neutrophil cascade of the present invention can alleviate the neurological deficit caused by brain tissue infarction and MCAO: wherein (A) TTC staining of brain tissue; (B) MRI imaging of brain tissue; (CD) quantification of infarct area; (E) EB perfusion of brain tissue; (F) body weight of MCAO / R mice; (G) Longa score; (H) Rotarod number; (I) survival curve;
[0027] Figure 6 Electron microscopic image of the effect of the neutrophil cascade-targeted drug delivery system of the present invention on the morphological changes of brain tissue mitochondria: wherein N: represents the nucleus; Mito: represents the mitochondria; the red arrow: represents the mitochondrial autophagosome;
[0028] Figure 7 The effect of the neutrophil cascade-targeted drug delivery system of the present invention on the opening and closing of the mitochondrial permeability transition pore in the hypoxia-reoxygenation model cells;
[0029] Figure 8 The results of the effect of the neutrophil cascade-targeted drug delivery system of the present invention on the mitochondrial membrane potential of the hypoxia-reoxygenation model cells are shown in the figure: JC-1monomers represents JC-1 as a monomer, which produces green fluorescence; JC-1aggregates represents JC-1 as an aggregate;
[0030] Fig. 9 The present invention is an investigation of the effects of the neutrophil cascade-targeted drug delivery system on the levels of TNF-α, IL-6, and IFN-γ in the supernatant of cells in a hypoxia-reoxygenation model. DETAILED DESCRIPTION
[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Give the sources of the raw materials and instrument models required for the following experiments.
[0033] Experimental Materials
[0034] 1. Mice, cell lines and liposomes
[0035] C57 mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., PC12 cell lines were purchased from Wuhan Pronocell Life Science Co., Ltd., and DSPE-PEG2K-Maleimide was purchased from MCE.
[0036] 2. The main instruments and equipment are shown in Table 1:
[0037] Table 1
[0038]
[0039]
[0040] 3. The main reagents and consumables are shown in Table 2:
[0041] Table 2
[0042]
[0043] Example 1: Preparation of MMP-9 responsive nanomedicine targeting neutrophils and mitochondria and encapsulating CsA: a neutrophil cascade-targeted drug delivery system.
[0044] S1. The NEBP peptide targeting neutrophils (sequence: CGEAIPMSIPPEVK), the MMP9 response peptide (sequence: PVGLIG) and the mitochondria-targeted peptide SS-31 (sequence: H2N-DArg-Dmt-Lys-Phe-NH2) were coupled at a molar ratio of 1:1:1 to obtain the MMP9-responsive peptide NEMSS (sequence: DArg-Dmt-Lys(Cys)-Phe-PVGLIG-GEAIPMSIPPEVK) targeting both neutrophils and mitochondria.
[0045] S2, using DSPE-PEG2K-Maleimide as a raw material, and forming a polymer with the peptide NEMSS having MMP9 response and targeting neutrophils and mitochondria prepared in step S1 on the surface of DSPE-PEG2K-Maleimide at a molar ratio of 1:1;
[0046] S3. The polymer, cyclosporin A (CsA), Cy5 dye, cholesterol and lipid are mixed in an organic solvent, vacuum dried into a thin film, and then phosphate buffered saline (PBS) is added and ultrasonicated for 10 minutes to obtain a neutrophil cascade-targeted drug delivery system.
[0047] The appearance of the neutrophil cascade-targeted drug delivery system was observed using a transmission electron microscope (TEM). An appropriate amount of CsA-M-Neu-NPs nanoparticles was dissolved in water to form a solution, then dripped onto a copper mesh, and after drying, the nanoparticle morphology was observed using a transmission electron microscope. The results were as follows: Figure 2 shown.
[0048] according to Figure 2 It can be seen that CsA-M-Neu-NPs present a spherical structure with a particle size between 95 and 105 nm.
[0049] Example 2: Neutrophil cascade-targeted drug delivery system targeting neutrophils and mitochondria
[0050] Neutrophils and PC12 cells extracted from mouse bone marrow were inoculated in 12-well plates, respectively. After culturing in an incubator for 4 hours, 1 μM CsA-M-Neu-NPs nanomedicine was added to the 12-well plates containing neutrophils and PC12 cells for co-culture for 2 hours, the culture medium was discarded and washed 3 times with PBS, 4% paraformaldehyde was added for fixation for 15 minutes, and then incubated with 0.5% TritonX-100 at room temperature for 20 minutes, and primary antibody was added at 4°C overnight. After washing with PBS, Ly6G secondary antibody / mitochondrial fluorescent probe was added and incubated at room temperature for 1 hour, and DAPI was added to counterstain the nucleus and incubated in the dark for 5 minutes. Finally, anti-fluorescence quencher was added, and laser confocal microscopy was used for observation and photography. The experimental results are shown in the figure. Figure 3 shown.
[0051] Depend on Figure 3 It can be seen that: Figure 3 A indicates that CsA-M-Neu-NPs nanomedicine can target the surface of neutrophils; Figure 3 B indicates that CsA-M-Neu-NPs nanomedicine can target mitochondria.
[0052] Example 3: Evaluation of the targeting effect of neutrophil cascade-targeted drug delivery system in the brain
[0053] In this example, the suture method was used to prepare a mouse ischemia-reperfusion (MCAO / R) model. The mouse was fixed on the operating table in a supine position and anesthetized continuously with low-concentration isoflurane. A constant temperature blanket was used during the operation to maintain body temperature. A midline incision was made in the mouse neck to expose the right external carotid artery, and an L1800 suture was inserted into the right internal carotid artery to occlude the right middle cerebral artery. The suture was removed after 90 minutes and reperfused for 6 hours. The Zea Longa score was used to verify whether the model preparation was successful. This experiment records the ability of CsA-M-Neu-NPs nanodrugs to penetrate the blood-brain barrier and target the site of ischemia-reperfusion injury. The specific operation steps are as follows:
[0054] In vivo NIR-II imaging: Mice in the sham operation group (Sham group) were injected with CsA-M-Neu-NPs through the tail vein, and mice in the ischemia-reperfusion group (MCAO / R) were also injected with CsA-M-Neu-NPs. At 1, 4, 8 and 24 h after administration, the mice were exposed to the NIR-II Kaer imaging system (KIS NIR-II, Kaer Laboratory, France) (808nm, 50mW cm-2) for 50ms (n=3 per group). Time-dependent NIR-II fluorescence images of brain tissue were obtained using in vivo imaging. Excitation was induced with an 808nm laser and filtered with an 808nm long-pass filter. Fluorescence emission was collected using an 1100nm bandpass filter with an exposure time of 50ms. Brain tissue was then taken and in vivo fluorescence imaging was performed for 24h. The experimental results are shown in the following figure. Figure 4 shown.
[0055] Depend on Figure 4 It can be seen that compared with the sham group, the intensity of the right brain NIR-II fluorescence signal of CsA-M-Neu-NPs increased significantly 1 hour after CIRI and in the subsequent period, and reached a peak at 24 hours. This indicates that CsA-M-Neu-NPs cross the damaged blood-brain barrier and accumulate in the brain parenchyma, and that the uptake efficiency of CsA-M-Neu-NPs in damaged brain tissue is higher.
[0056] Example 4: Changes in body weight and neurological function evaluation of mice after administration of the neutrophil cascade-targeted drug delivery system
[0057] This example records the changes in the weight of mice and the neurological function scores after administration of the neutrophil cascade targeted drug delivery system. Through MRI imaging, TTC staining, EB staining, etc., it is evaluated whether the neutrophil cascade targeted drug delivery system can better reduce brain tissue infarction and restore the blood-brain barrier.
[0058] 4.1. TTC staining.
[0059] On the third day, mice were euthanized (n = 3 / group). The brain was cut into 6 slices of 2 mm thickness and incubated in 2% 2,3,5-triphenyltetrazolium chloride (TTC). The slices were incubated in TTC solution at 37°C for 20 min. The infarct area was measured using Image J analysis software. Unstained brain sections were defined as the infarct area. The infarct area was indirectly measured by subtracting the total area of the non-infarcted hemisphere from the non-infarcted hemisphere. The formula for calculating the percentage of hemisphere infarct area is: infarct volume / total volume of the non-infarcted hemisphere × 100%. The experimental results are shown in Figure 5 A and Figure 5 As shown in C.
[0060] Depend on Figure 5 A and Figure 5 C shows that compared with the sham operation group (Sham group), the right cerebral infarction area in the ischemia-reperfusion group (MCAO / R group) and CsA-M-Neu-NPs group was significantly increased (***P<0.001); compared with the ischemia-reperfusion group (MCAO / R group), CsA-M-Neu-NPs treatment can significantly reduce the cerebral infarction area of mice (##P<0.01).
[0061] 4.2 Magnetic Resonance Imaging (MRI)
[0062] Magnetic resonance imaging: MRI was performed on a 3.0T MRI scanner (Trio, Semiens, Germany) and a 7.0T CG NOVILA system (Shanghai Chenguang Medical Technology Co., Ltd., China) to generate T2-weighted images. Under isoflurane anesthesia, mice were imaged continuously on the third day after ischemia-reperfusion (5 mice per group). Image J software was used to evaluate the cerebral infarction area from the high signal area of the T2-weighted images. The experimental results are shown in Figure 5 B and 5D.
[0063] Depend on Figure 5 B and 5D show that MRI was used to evaluate the effect of CsA-M-Neu-NPs on the cerebral infarction area after CIRI ( Figure 5 B). We evaluated the infarct extent by T2-weighted imaging sequence. Compared with the ischemia-reperfusion group (MCAO / R group), the infarct area in the CsA-M-Neu-NPs group was significantly reduced (##P<0.01).
[0064] 4.3. Blood-brain barrier disruption test (EB staining)
[0065] The breakdown of the blood-brain barrier was assessed by the EB (MACKLIN, Shanghai, China) leakage technique. A 4% dye solution (2.5 mL kg-1) was injected through the tail vein on the third day after CIRI. After 6 hours of circulation, heparinized saline was perfused transcardially, and then the brain was removed (n = 6 per group). A photo of the brain was taken before dividing it into the left and right hemispheres. Each hemisphere was weighed and homogenized in PBS. The homogenate was centrifuged at 14,000 × g for 20 min at 4°C using a microcentrifuge, and then an equal volume of 50% trichloroacetic acid was added to the collected supernatant. The experimental results are shown in Figure 2. Figure 5 E.
[0066] Depend on Figure 5 E It can be seen that: In order to determine whether drug treatment can reverse the decreased BBB integrity caused by CIRI, we evaluated the permeability of the BBB. Compared with the ischemia-reperfusion group (MCAO / R group), the EB permeability in the CsA-M-Neu-NPs group was significantly reduced on the third day after CIRI, indicating that CsA-M-Neu-NPs treatment can partially restore the integrity of the BBB.
[0067] Example 5: Transmission electron microscopy observation of mitochondrial morphology
[0068] After the mice were treated with MCAO / R and medication according to the groups, the brain tissues of the ischemic injury sites of the mice were taken and cut into 1 mm3 small pieces on a pre-cooled wax plate, fixed with 2.5% glutaraldehyde and 1% osmium acid, dehydrated with gradient ethanol, immersed in epoxy resin 812-acetone 2:1, embedded in epoxy resin 812, sliced, stained with saturated uranyl acetate water, washed with water, dried, and stained with lead citrate solution and observed under an electron microscope. The results are as follows Figure 6 .
[0069] Depend on Figure 6 It can be seen that the mitochondrial membrane structure of the brain tissue of each mouse in the sham operation group (Sham group) was intact, the mitochondrial cristae were clear, and the morphology was normal. The mitochondria in the ischemia-reperfusion group (MCAO / R group) and the CsA-M-Neu-NPs group were swollen, vacuolated severely, the mitochondrial cristae disappeared, and mitochondrial autophagosomes appeared. After CsA-M-Neu-NPs treatment, the degree of mitochondrial morphological damage was alleviated.
[0070] Example 6: mPTP opening level detection
[0071] After PC12 cells were treated with hypoxia / reoxygenation (OGD / R) and drugs according to the grouping, they were washed with calcium-free benchtop solution, 2μmol·L-1 calcein AM and 100nmol·L-1 mitochondrial fluorescent probe (mito tracker) were added, and incubated at room temperature in the dark for 30 minutes. After washing, 2mmol·L-1 cobalt chloride (CoCl2) was added and incubated for 15 minutes. After washing, fresh calcium-free benchtop solution was used, and photos were taken and analyzed with a fluorescence microscope. The experimental results are shown in Figure 2. Figure 7 .
[0072] Depend on Figure 7 It can be seen that compared with the control group (Control group), the green fluorescent bright spots in the hypoxia-reoxygenation group (OGD / R group) and the CsA-M-Neu-NPs group were significantly reduced; compared with the hypoxia-reoxygenation group (OGD / R group), the green fluorescent bright spots recovered to varying degrees after the action of CsA-M-Neu-NPs, indicating that the openness of mPTP was significantly reduced.
[0073] Example 7: JC-1 detection of mitochondrial membrane potential level
[0074] JC-1 is an ideal fluorescent probe widely used to detect mitochondrial membrane potential ΔΨm. It can detect the mitochondrial membrane potential of cells, tissues or purified mitochondria. When the mitochondrial membrane potential is high, JC-1 aggregates in the matrix of mitochondria to form polymers (J-aggregates), which can produce red fluorescence; when the mitochondrial membrane potential is low, JC-1 cannot aggregate in the matrix of mitochondria. At this time, JC-1 is a monomer and can produce green fluorescence. In this way, it is very convenient to detect changes in mitochondrial membrane potential by changing the fluorescence color. After PC12 cells were treated with OGD / R and drug administration according to the grouping, the culture medium of each well was aspirated, the cells were washed twice with PBS, 1mL of culture medium was added, 1mL of JC-1 staining working solution was added, mixed thoroughly, and incubated at 37℃ for 30min. During the incubation, the JC-1 staining buffer was prepared and placed in an ice bath. After the incubation at 37°C, the cells were washed twice with JC-1 staining buffer (on ice) according to the instructions of the mitochondrial membrane potential detection kit and observed under a fluorescence microscope. The experimental results are shown in Figure 8 .
[0075] Depend on Figure 8 It can be seen that: under the fluorescence microscope, the red fluorescence of mitochondrial membrane potential in the control group (Control group) was more obvious; the green fluorescence in the hypoxia-reoxygenation group (OGD / R group) and the CsA-M-Neu-NPs group increased significantly; after treatment with CsA-M-Neu-NPs, the red fluorescence recovered to varying degrees, indicating that the mitochondrial membrane potential level had recovered.
[0076] Example 9: Detection of inflammatory related factors
[0077] According to the instructions of the kit, the ELISA method was used to determine the content of TNF-α, IL-6, and IFN-γ in the cell supernatant. The dilution, sample addition, washing, enzyme-labeled antibody addition, color development, colorimetry and other operations were performed step by step. The blank control well was used for detection by an ELISA instrument, and the absorbance (A) of each well was measured. Then, the corresponding TNF-α, IL-6, and IFN-γ content was calculated on the regression equation based on the A of the sample. The experimental results are shown in the figure. Fig. 9 .
[0078] Depend on Fig. 9 It can be seen that compared with the control group (Control group), the levels of IL-6 and IFN-γ in the hypoxia-reoxygenation group (OGD / R group) and the CsA-M-Neu-NPs group were significantly increased; compared with the hypoxia-reoxygenation group (OGD / R group), CsA-M-Neu-NPs could significantly reduce the levels of TNF-α and IFN-γ, indicating that it can reduce the content of inflammatory factors in the hypoxia-reoxygenation model.
[0079] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.
[0080] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.
Claims
1. A method for preparing a neutrophil cascade-targeted drug delivery system, characterized in that: The preparation method comprises the following steps: S1. The NEBP peptide targeting neutrophils (sequence: CGEAIPMSIPPEVK), the MMP9 response peptide (sequence: PVGLIG) and the mitochondria-targeted peptide SS-31 (sequence: H2N-DArg-Dmt-Lys-Phe-NH2) were coupled to obtain the peptide NEMSS (sequence: DArg-Dmt-Lys(Cys)-Phe-PVGLIG-GEAIPMSI PPEVK) that is MMP9-responsive and simultaneously targets neutrophils and mitochondria; S2, using DSPE-PEG2K-Maleimide as raw material, modifying the NEMSS peptide on the surface of DSPE-PEG2K-Maleimide; S3. The polymer, cyclosporin A (CsA), Cy5 dye, cholesterol and lipid are mixed in an organic solvent, vacuum dried into a thin film, and then phosphate buffered saline (PBS) is added and ultrasonicated for 10 minutes to obtain a neutrophil cascade-targeted drug delivery system.
2. The method for preparing a neutrophil cascade-targeted drug delivery system according to claim 1, characterized in that: The molar ratio of the NEBP peptide, the MMP9 response peptide and the mitochondria-targeted polypeptide SS-31 is 1:1:
1.
3. The method for preparing a neutrophil cascade-targeted drug delivery system according to claim 1, characterized in that: The molar ratio of the DSPE-PEG2K-Maleimide to the NEMSS polypeptide is 1:
1.
4. The method for preparing a neutrophil cascade-targeted drug delivery system according to claim 1, characterized in that: The molar ratio of the polymer, CsA drug and Cy5 dye is 5:1:0.
2.
5. The method for preparing a neutrophil cascade-targeted drug delivery system according to claim 1, characterized in that: The organic solvent is dichloromethane.
6. A neutrophil cascade-targeted drug delivery system prepared by the preparation method according to any one of claims 1 to 5.
7. A neutrophil cascade targeted drug delivery system according to claim 6, characterized in that: The CsA-M-Neu-NPs nano-drug presents a spherical structure, and the particle size of the CsA-M-Neu-NPs lipid nano-drug is 90-200 nm.
8. Use of a neutrophil cascade-targeted drug delivery system as claimed in claim 6 or 7 in the preparation of a drug for treating cerebral ischemia-reperfusion injury.
9. Use of a neutrophil cascade-targeted drug delivery system as claimed in claim 6 or 7 in the preparation of a drug for treating inflammation-related diseases.
10. Use of a neutrophil cascade-targeted drug delivery system as claimed in claim 6 or 7 in the preparation of a drug carrier targeting neutrophils.
Citation Information
Patent Citations
Amphiphilic prodrug for mitochondrial targeted therapy and preparation method and application of nanoparticles of amphiphilic prodrug
CN114870000A
Drug delivery system in targeted combination with neutrophil
CN117224696A
Preparation method of tumor microenvironment responsive immune liposome
CN117379562A
Neutrophil elastase binding peptides and compositions thereof
US20230235022A1
Targeted polypeptide-modified drug-loaded lipoprotein nano-drug delivery system, and preparation and application thereof
WO2021031839A1
Cited By
Mitochondria-targeted carthamin yellow nanoparticles and application thereof
CN121774919A
